chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Finger swollen all time; Finger swollen all time and hurts/finger stays swollen all the time and hurts, some redness and swelling not lot of pain; Finger swollen all time and hurts/redness; Patient received second dose on 10-Feb-2021 and first booster on 30-Mar-2021; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Finger swollen all time), PAIN IN EXTREMITY (Finger swollen all time and hurts/finger stays swollen all the time and hurts, some redness and swelling not lot of pain), ERYTHEMA (Finger swollen all time and hurts/redness) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose on 10-Feb-2021 and first booster on 30-Mar-2021) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    The patient's past medical history included Swelling of fingers and Localized erythema. Concurrent medical conditions included Arthritis rheumatoid.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On 10-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Mar-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose on 10-Feb-2021 and first booster on 30-Mar-2021). On an unknown date, the patient experienced PERIPHERAL SWELLING (Finger swollen all time), PAIN IN EXTREMITY (Finger swollen all time and hurts/finger stays swollen all the time and hurts, some redness and swelling not lot of pain) and ERYTHEMA (Finger swollen all time and hurts/redness). At the time of the report, PERIPHERAL SWELLING (Finger swollen all time), PAIN IN EXTREMITY (Finger swollen all time and hurts/finger stays swollen all the time and hurts, some redness and swelling not lot of pain), ERYTHEMA (Finger swollen all time and hurts/redness) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose on 10-Feb-2021 and first booster on 30-Mar-2021) outcome was unknown.            It was unknown if patient was enrolled in COVID-19 vaccine trial.  No concomitant medications were provided.  The causality relationship between co-suspect Rinvoq and event swelling of finger was reported as not related.  The causality relationship between co-suspect Rinvoq and events pain in finger, localized erythema was reported as not reported.  No treatment medications were provided.
Contracted covid-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted covid-19) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Contracted covid-19). At the time of the report, COVID-19 (Contracted covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Feb-2021 and was forwarded to Moderna on 24-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted covid-19) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Contracted covid-19). At the time of the report, COVID-19 (Contracted covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
7/26/07 9:47 AM, left sided pain arm, shoulder, leg/redness at injection site/temp 101 F. Pt went to ER where he reports he was advised to take Benadryl, given antibiotic and advised to ice area.
This spontaneous case, initially received from other health professional on 24-Oct-2018, concerns a 2-year-old, male child patient. The patient had no medical history and did not administer any concomitant medications. On 24-Oct-2018, the patient (under age of 4 years) was administered FLUCELVAX QIVc [dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 252664, and expiry date: 30-Jun-2019]. At the time of this report, no adverse events was reported after the vaccine administration and no treatment measures were taken. The reporter assessed this case as non-serious.
Pt complained of nausea, vertigo, diarrhea, tinnitus, stiffness and pain on (L) side of neck & at site.
Patient had redness measuring 7-8 cm around injection site, shortness of breath.  Emergency services were notified and she was transported to Medical Center.  She was admitted for Acute Hypoxic Respiratory Failure and COPD Exacerbation.  She is still admitted at Medical Center.
Initial unsolicited report received from a consumer (Patient) on 06-Mar-2017. This case involves a 34-year-old male patient who was vaccinated with a first dose of SMALLPOX VACCINE (Batch number, expiry date, dose form frequency and route and of administration not reported) in the left deltoid on 25-Feb-2017. The patient denied any pre-existing physician diagnosed allergies, birth defects, medical conditions (specify) and Illness at time of vaccination. Concomitant medications were not reported. Any other vaccines with four weeks of vaccination were not reported. On 04-Mar-2017, seven days following the vaccination the patient developed a rash at the injection site of the area around the Band Aid and spread to the entire deltoid region. Relevant laboratory investigations and corrective treatment were not reported. The outcome of the events was unknown. List of documents held by the sender: None.
Patient was given PEDARIX and Polio vaccines when he needed Dtap and Polio only. He got an extra dose of Hep B and extras dose of Polio. Mother stated that he got a fever the next day and has a small bump on his right arm. She gave him TYLENOL for the fever and it went away. The bump is still there and will use hot compress on the arm.
This spontaneous report as received from a nurse practitioner refers to a 6 year old patient of unknown gender. The patient's pertinent medical history and concurrent conditions were not reported. No previous drug reactions or allergies were reported. On 28-MAR-2016 the patient was inadvertently vaccinated with expired dose of PROQUAD (Merck) (dosing details were not reported) (lot # K014798 expiry date of 12-MAR-2016). No concomitant medications were reported. No adverse effects were reported. There was no product quality complaint involved. Additional information has been requested.
Information has been received from a pharmacist, referring to 3 patients of unknown age and gender. The patients' medical history, concomitant therapy and concurrent condition were not provided. On unknown dates, the patients were vaccinated with 3 doses of improperly stored PNEUMOVAX 23 (lot # L014458, expiration date 11-FEB-2017) for prophylaxis. The vaccines were stored at 62 degrees Fahrenheit (F) for 11 hours. The previous temperature excursion was recorded as 51F for 13 hours 30 minutes. No adverse effects were reported. The outcome of events was unknown. Follow up information was received from a worker from the pharmacist's office on 22-FEB-2017. The reporter noted there was only one vaccine given on 17-DEC-2016, and the patient's initials were identified. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1612USA011009.
Hives; additional symptoms; This case was reported by a other health professional via sales rep and described the occurrence of hives in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Bexsero and Menveo. On an unknown date, unknown after receiving Bexsero and Menveo, the patient experienced hives and adverse reaction. On an unknown date, the outcome of the hives and adverse reaction were unknown.   It was unknown if the reporter considered the hives and adverse reaction to be related to Bexsero and Menveo.  Additional details were provided as follows: The age at vaccination was not reported. The patient was given Menveo and Bexsero vaccinations at separate sites at the same visit.  The patient developed hives and additional symptoms over a few days and had decided to seek medical attention from an allergist for more testing and information. Lot number and additional information was unavailable at the time of call.
Wound up being in bed for most of that day; This is a spontaneous report received from a contactable consumer. A adult male patient received unknown dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), Solution for injection, via an unspecified route of administration on 22Mar2021 as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. It was unknown if the patient received any other vaccines within 4 weeks prior to the COVID vaccine. It was unknown if the patient was diagnosed with COVID-19 prior to vaccination and if he was tested for covid-19 since vaccination. On 22Mar2021, the patient wound up being in bed for most of that day. It was unknown if patient received any treatment due to adverse events. The event was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
8:55 patient complained of feeling anxious, fluttering in chest per patient this is not new, history of Mitral valve prolapse, Diabetes mellitus and COPD. Lost her spouse on this day, feeling anxious.   9:15- 128/60 Pulse 84, respiration 70, 97% saturated  Patient denied chest pain or shortness of breath. No sign of distress observed.  9:30 -Patient instructed to call EMS for chest pain and shortness of breath, fluttering, contact Primary care provider. Patient verbalized understanding and drove home.
Second day after shot child was lethargic, irritable, decreased appetite, and decreased awareness. Before vaccine child was very active and interacted with us. Child's health began to deteriorate after vaccine was administered. At child's fifteen month wellness check up nurse ordered blood tests for child to find out why child was so weak and not recovering from current illnesses.
Immunizations given at 10am, that night child went to bed and woke up "choking" and mom noticed he was hot and having trouble breathing. 911 was called and paramedics told parents "its a febrile seizure and the child does not need to go to the ER". A few months later he had another fever and a seizure, he recovers well from these seizures.
Focal seizures (staring, drooling, generalized jerking) for > 15 min. the morning after receiving MMR, VARIVAX, DTAP, IPV. Transferred to PICU.
Pt called about a month after her second dose. She had been to the dentist and was asked why her tongue was white, splotchy, and had blisters. She also had a bitter taste in her mouth. Pt noticed some soreness while brushing her teeth before going to the dentist that day, but nothing previously. Pt was not sure if it was from the vaccination.
190 patients (9 different lot numbers) received a vaccine past the beyond used by date; no adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date) and NO ADVERSE EVENT (no adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (190 patients (9 different lot numbers) received a vaccine past the beyond used by date).    This case is of 17 out of 190 patients. No concomitant medication were reported. Patient received a vaccine past the beyond used by date. No treatment medication were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-704335 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704335:CASE
Tachycardia,Trembing hands,fatigue,hyperthyroidism,graves disease,mediastinal mass,lymph nodes.  Xrays,ct scan,mei,pet scan ,countless bloodwork,biopsy Mediastinoscopy
Information has been received from a physician, for the Pregnancy Registry for GARDASIL concerning a 26 year old female with a history of polycystic ovaries, irregular periods, absence of menstruation (August 2007), Papanicolaou smear abnormal (low grade 2007) and biopsy (July 2007, showed no dysplasia) who on 07-NOV-2007 was vaccinated intramuscularly with a first dose of GARDASIL (Lot # 658282/0929U) and on 04-FEB-2008 was vaccinated intramuscularly with a second dose of GARDASIL (Lot # 659653/1448U). There was no concomitant medication. The physician reported that the patient received 2 doses of the vaccine and is pregnant. The patient had a negative pregnancy test on 02-FEB-2008. On 05-FEB-2008 she had a positive qualitative HCG test (LMP 26-DEC-2007). The patient was seen in the office for unspecified medical attention. The patient was given a slip on 25-FEB-2008 to have routine OB panel. On 25-FEB-2008 the ultrasound showed the fetus to be 7 weeks and 6 days. No product quality complaint was involved. Outcome unknown. Follow-up information has been received from the physician on 10-NOV-2008. It was reported that this was the patient's first pregnancy. Medication taken during pregnancy included duet DHA prenatal vitamin, daily and Fe supplement, daily, for 9 months of pregnancy. Prenatal testing included MSAFP for Down's syndrome, screen negative, on 24-APR-2008. Subsequently, a healthy female infant was delivered at 38.5 weeks from LMP by cesarean section due to compound presentation on 26-SEP-2008. Birth weight was 7 pound 12 ounce, length 21.5 inch. The cesarean section was recommended due to non-vertex presentation. The infant was normal and with no congenital anomalies; there were no complications during pregnancy. The patient's concurrent medical condition included obesity. No further information is available.
Developed emesis (5+ many episodes), petechia of eyes and face thought due to vomiting the next day.
This infant had vaccine administered on 04/09/01. On 04/11/01, he presents with right arm edema at the injection site down to the wrist. The patient was seen by the doctor at the health center.
Ever since patient received the vaccine patient have been getting hives; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Ever since patient received the vaccine patient have been getting hives) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced URTICARIA (Ever since patient received the vaccine patient have been getting hives). At the time of the report, URTICARIA (Ever since patient received the vaccine patient have been getting hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided by the reporter
1 of 2 pts vaxed w/Tetramune/OPV who exp an adverse event;pt vaxed 30JAN95 & exp an abn, high pitched cry x 4hrs following vax;also devel induration @ inj site w/in 24hrs (size unk);MD visit-nl exam;pt recovered;
Patient had itchy eyes after the first dose and had proactively bought benadryl. Patient started to experience itchy eyes a few minutes after the second dose and began having itching/swelling of the throat after 25 min from the dose. patient has been taking benadryl daily, last dose was yesterday (09/06/21)
Deltoid muscles (noticeably more than even tetaus vax) and less so joint soreness R shoulder, possibly slight fatigue - started approx >6hrs after shot. Did a 40min dance workout (a little sluggishly) but doable. Hot tub x 15 min, naprosyn, and feel good now despite some fatigue (which may be unrelated to vaccine).
I went out on December 31st and wasn't feeling well. I had the sniffles. I thought it was just a cold, but I tested myself for COVID-19 and it was positive. I called my physician who prescribed PAXLOVID and by 01/07/2023, everything was gone, but I went ahead and finished the prescription.
3/16/2021 Received 2nd Moderna Covid-19 vaccine 3/25/2021 Trouble breathing when exercising so stopped after 5 min and usually do 20 mim; temp elevated for me normal 97.6 and was between 98.6 and 99.3, hacking up yellowish phelgm. Phelgm had been coming up for longer period of time. 3/26/2021 went to clinic and put on treatment for possible bronchitus. Z-Pak and Prednisone 5 days and asked to schedule x-ray to see if something more showed. 3/30/2021 Completed meds and x ray scheduled. No improvement in breathing 4/1/2021 was finally able to get chest x-ray 4/2/2021 x-ray showed nodule on lung & calcified grandular - told to schedule ct to check out nodule -  told clinic still no change in condition  4/5/2021 called clinic again due to pain overnight in left lung. Trouble getting ct scheduled so clinic sent to me emergency room rather than schedule ct 4/5/2021 - At ER blood work, x-ray and ct scan completed.  CT chest was significant for large bilateral pulomanry emboli w r ventricular strain. Also r middle lobe lung nodule and r adrenal nodule. Started on heparin drip and admitted. Hospitalized 4/5 and sent home 4/8. Sent home on Xarelto to continue at least 3 months and consult w family doctor to determine cause of submassive clots and further treatment.
Had the symptoms, hurts a lot; Burning sensation, fire sensation; Burning sensation or electricity does not go away; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced pain (Verbatim: Had the symptoms, hurts a lot), burning sensation (Verbatim: Burning sensation, fire sensation) and electric shock sensation (Verbatim: Burning sensation or electricity does not go away). The outcome of the pain, burning sensation and electric shock sensation were not resolved.   It was unknown if the reporter considered the pain, burning sensation and electric shock sensation to be related to Shingles vaccine.     It was unknown if the company considered the pain, burning sensation and electric shock sensation to be related to Shingles vaccine.   Additional Information: GSK receipt date: 25-MAR-2023 This case was reported by a patient via interactive digital media. The patient put on the shingles vaccine and got all the symptoms but got not blisters it's been 5 months and it still hurts a lot and that burning sensation or electricity does not go away patient don't know what to do. The follow-up could not be possible as no contact details were available. This report was one of several cases received as part of a line-listing, each containing minimal information.
Pt received 1st dose of vaccine on 9 FEB and received 2nd dose 8-10 days earlier than recommended time frame which is on 26 FEB. Pt reported expected flu-like symptoms the night of 26 FEB until the morning of 28 FEB. Pt reported body ache, headache, soreness at the injection site. Pt reported taking tylenol on 27 FEB. Pt reported no symptoms and back to normal on the night of 28 FEB. Pt reported NO adverse reaction from receiving early 2nd dose of the vaccine.
Dizziness; Headache (oppressive); Fatigue; Loopy feeling; Sleep for hours at a time during the day and full night sleep when not disturbed by headache; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 12:30 (at the age of 54-year-old), as a single dose for COVID-19 immunisation. Medical history included becker's muscular dystrophy carrier, weight (overweight) seasonal allergy, and allergy to dogs, cats other small animals. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included naproxen sodium (ALEVE) and loratadine (reported as generic claritin); for unknown indications from unknown start dates and unknown if ongoing. On 25Apr2021 at 12:45, the patient experienced dizziness within 15 minutes of shot, oppressive headache, fatigue, loopy feeling and slept for hours at a time during the day and full night sleep when not disturbed by headache. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with ibuprofen (ADVIL), respiratory evaluation and heart monitoring. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness, oppressive headache, fatigue, loopy feeling and sleep for hours at a time during the day and full night sleep was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.